A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells
- 1 June 2012
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 13 (8) , 681-693
Abstract
Previously, we demonstrated potent antineoplastic activity of a distinctive histone deacetylase inhibitor (HDACI), AR42, against chemoresistant CP70 ovarian cancer cells in vitro and in vivo. Here,...Keywords
This publication has 75 references indexed in Scilit:
- Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomasThe Laryngoscope, 2011
- Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphomaLeukemia Research, 2011
- Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagyCancer, 2011
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death & Differentiation, 2011
- Principles and Strategies for Developing Network Models in CancerCell, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The promises and perils of p53Nature, 2009
- Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression?Nature Clinical Practice Oncology, 2008
- Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes ApoptosisMolecular Cell, 2007
- The Epigenomics of CancerCell, 2007